{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-058701","form_type":"8-K","ticker":"STRO","cik":"0001382101","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.174461+00:00","generated_at":"2026-06-02T02:02:38.500853+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Sutro Biopharma Q1 2024: Revenue $13.0M, Cash $267.6M; IND cleared for NSCLC trial","bullets":["Q1 2024 revenue of $13.0M (vs $12.7M YoY); total operating expenses $69.6M ($56.9M R&D, $12.7M G&A).","Cash and investments $267.6M plus $45.6M in Vaxcyte shares; April added $75M from Ipsen licensing and $75M equity offering.","IND cleared for luvelta in NSCLC; Phase 2 expected to start H2 2024, initial data H1 2025.","REFRαME-O1 registration trial for PROC now enrolling; pediatric AML trial expected to begin H2 2024.","STRO-003 licensed to Ipsen; Sutro eligible for up to $899M in milestones plus tiered royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-058701","json":"https://secwatch.observer/filing/0000950170-24-058701.json","markdown":"https://secwatch.observer/filing/0000950170-24-058701.md","text":"https://secwatch.observer/filing/0000950170-24-058701.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382101/000095017024058701/0000950170-24-058701-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382101/000095017024058701/stro-20240513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:02:38.500853+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1b42e4e68c0967c92f27df1c386838d4b13c66a2","claim":"SUTRO BIOPHARMA, INC. reported the quarter ended March 31, 2024 results: revenue $13.0 million, net income $267.6 million.","evidence_excerpt":"stock on the last trading day of each reporting period, with any non-operating, unrealized gains and losses recorded in Sutro’s statements of operations. Revenue Revenue was $13.0 million for the quarter ended March 31, 2024, as compared to $12.7 million for the same period in 2023, with the 2024 amount related principally to the Astellas collaboration, and the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017024058701/0000950170-24-058701-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$13.0 million"},{"label":"Net income","value":"$267.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}